摘要
【目的】分析依折麦布联合辛伐他汀对慢性肾炎伴高血压患者心肾保护作用。【方法】将本院收治的72例慢性肾炎伴高血压患者按就诊及住院顺序编号，随机分为两组，每组36例。对照组单用辛伐他汀治疗，观察组加用依折麦布治疗，观察比较患者心肾功能的改善情况。【结果】用药前两组各相关指标相比较差异无显著性（P〉0．05），用药12周后，两组24h尿蛋白定量、血尿素氮（BUN）、肌酐（SCr）、β2-微球蛋白（β2-MG），总胆固醇（TC）、高密度脂蛋白（HDL—C）等指标较同组治疗前均有所改善，炎症因子均显著下降（P〈0．05），观察组较对照组改善更为显著（P〈0．05），两组收缩压（SBP）、舒张压（DBP）均明显改善，但组间比较差异无显著性（P〉0．05）。观察组随访非致死心梗、冠心病死亡、未知非出血性卒中、冠脉血运重建及严重冠脉硬化发生率均略低于对照组，但两组相比较差异均无显著性（P〉0．05）。【结论】采用依折麦布联合辛伐他汀方案治疗慢性肾炎伴高血压，其心肾保护作用好且安全性高。
[Objective]To analyze the cardio-renal protection effects of ezetimibe combined with simvastatin in patients with chronic nephritis complicated with hypertension. [MethodslSeventy-two cases of patients with chron- ic nephritis complicated with hypertension treated in our hospital were studied. According to the order of medical treatment and hospitalization, they were randomly divided into the control group and the observation group, each with 36 cases. The control group were treated with simvastatin alone while the observation group were treated ad- ditionally with ezetimihe. The improvement of eardi--renal function in patients was observed. The two groups were followed up for three years and the long-term effect was observed. [Results]Before treatment, there were no differences in renal function indexes, blood pressure, blood lipid indexes, and inflammatory factor levels between the two groups （ P 〉0.05）. 12 weeks after treatment, the 24h urinary protein quantitation, Ser, beta 2-MG, BUN, and other indicators in the two groups were improved, compared with the groups themselves prior to treat- meat. The improvement in the observation group was the most significant （ P 〈0.05）. DBP and SBP in the two groups were significantly improved after treatment, but the improvement was not statistically significant different between the two groups （P〉0.05）. TC and LDL-C in the observation group were improved significantly. Corn pared with those in with the same group before treatment and those in the control group after treatment, the difference was statistically significant （ P 〈0.05）. Inflammatory factors decreased significantly compared with those in with the same group before treatment and after treatment, the differences were statistically significant （P 〈0.05）. The incidence rates of non-fatal myocardial infarction, coronary heart disease death, unknown non-hem orrhagic stroke, coronary revascularizatioa, and severe coronary atheroselerotic events in the observation group were sligh
出处
《医学临床研究》
CAS
2016年第4期686-689,共4页
Journal of Clinical Research
